RPRX
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Royalty Pharma plc (RPRX) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B+); its weakest is Growth (C-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | C (2.5) | C- (1.9) | B+ (3.5) | B+ (3.6) | C+ (2.6) | C+ (2.8) |
| 2026-11-07 | C (2.4) | C- (1.9) | B+ (3.5) | B+ (3.5) | C+ (2.7) | C+ (2.8) |
| 2026-10-31 | C+ (2.6) | C- (1.9) | B+ (3.8) | B+ (3.5) | C+ (2.7) | B- (2.9) |
| 2026-10-24 | C+ (2.6) | C- (1.9) | A- (3.9) | B (3.2) | C+ (2.6) | C+ (2.8) |
| 2026-10-17 | C+ (2.7) | C- (1.9) | A- (3.9) | B (3.2) | C+ (2.6) | B- (2.9) |